The U.S. Food and Drug Administration (FDA) has cleared the Cynosure PicoSure picosecond laser for removal of the full spectrum of tattoo inks and pigmented lesions. The device now features a new 1064nm wavelength to remove black and other dark tattoo inks along with the existing 532nm and 755nm wavelengths. The new wavelength will be offered as an upgrade to existing PicoSure customers, and is expected to be available later this year.
Recent research presented at the American Society for Laser Medicine & Surgery Annual Conference showed PicoSure as a treatment for melasma and added further support for tattoo removal. “PicoSure is widely recognized by aesthetic practitioners for its unsurpassed clinical efficacy and proven performance,” says CEO Michael Davin. “Consumers simply know it works. With the FDA clearance of the 1064nm Laser Delivery System we believe our picosecond technology has the broadest range of clearances on the market. The new wavelength builds on our aesthetic industry leadership and expands PicoSure’s versatility for tattoos, pigmentation and skin revitalization.”